Krystal Biotech (KRYS) EBITDA (2016 - 2026)

Krystal Biotech has disclosed EBITDA across 11 years of filings, most recently posting $53.2 million for Q1 2026.

• EBITDA for Q1 2026 came in at $53.2 million, up 46.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $223.0 million (up 78.92% YoY), and the FY2025 annual result was $206.2 million, up 133.39% from the prior year.
• EBITDA came in at $53.2 million for Q1 2026 at Krystal Biotech, up from $51.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $80.6 million in Q3 2023 to a low of -$51.0 million in Q1 2022.
• The 5-year median for EBITDA is $15.2 million (2024), against an average of $12.9 million.
• Across the five-year window, EBITDA slumped 222.47% in 2022 and soared 726360.0% in 2025, its largest moves.
• Krystal Biotech's EBITDA stood at -$31.3 million in 2022, then surged by 131.02% to $9.7 million in 2023, then jumped by 350.75% to $43.8 million in 2024, then grew by 17.5% to $51.4 million in 2025, then grew by 3.38% to $53.2 million in 2026.
• The last three EBITDA figures came in at $53.2 million (Q1 2026), $51.4 million (Q4 2025), and $79.3 million (Q3 2025), per Business Quant data.